Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Withdrawn 1Terminated 1

Sponsor Class

OTHER_GOV 1OTHER 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gynecologic 4Breast 2Thoracic 1Other solid neoplasm 1Gastrointestinal 1

Conditions

Locally Advanced Breast Cancer 1Breast Neoplasms 1

Interventions

Trastuzumab 696Paclitaxel 679Cyclophosphamide 634Docetaxel 554Capecitabine 468Letrozole 407Carboplatin 393Fulvestrant 379Doxorubicin 330Tamoxifen 288pembrolizumab 272Anastrozole 252Epirubicin 249exemestane 238pertuzumab 229Bevacizumab 214Radiotherapy 213Gemcitabine 211Vinorelbine 188palbociclib 183Lapatinib 175130-nm albumin-bound paclitaxel 168Albumin-Bound Paclitaxel 156Exercise 147Magnetic Resonance Spectroscopy 145eribulin 144Taxes 134Fluorouracil 131Everolimus 118Cisplatin 118

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Hydralazine × Breast × Clear all
NCT00575978 2015-03-04

Hydralazine as Demethylating Agent in Breast Cancer

University of Arkansas

Phase 1/2 Withdrawn
Breast

Breast Neoplasms

NCT00395655 2006-11-03

Hydralazine and Valproate Added to Chemotherapy for Breast Cancer

National Institute of Cancerología

Phase 2 Terminated
43 enrolled
Breast

Locally Advanced Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡